Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Trastuzumab, and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
NCT06123338Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2024
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, trastuzumab in Esophagogastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
Esophagogastric Cancer
Beyond the preview
Go deeper on NCT06123338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123338.